First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

S. Buti; M. Bersanelli; F. Maines; G. Facchini; F. Gelsomino; F. Zustovich; M. Santoni; E. Verri; U. De Giorgi; C. Masini; F. Morelli; M.G. Vitale; T. Sava; G. Prati; C. Librici; A.P. Fraccon; G. Fornarini; M. Maruzzo; F. Leonardi; O. Caffo

doi:10.1016/j.clgc.2016.12.024

First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

S. Buti, M. Bersanelli, F. Maines, G. Facchini, F. Gelsomino, F. Zustovich, M. Santoni, E. Verri, U. De Giorgi, C. Masini, F. Morelli, M.G. Vitale, T. Sava, G. Prati, C. Librici, A.P. Fraccon, G. Fornarini, M. Maruzzo, F. Leonardi, O. Caffo

Research output: Contribution to journal › Article › peer-review

Abstract

Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. © 2016 Elsevier Inc.

Original language	English
Pages (from-to)	e609-e614
Journal	Clinical Genitourinary Cancer
Volume	15
Issue number	4
DOIs	https://doi.org/10.1016/j.clgc.2016.12.024
Publication status	Published - 2017

Keywords

Chromophobe RCC
First-line treatment
nccRCC
Papillary RCC
Pazopanib

Access to Document

10.1016/j.clgc.2016.12.024

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009771922&doi=10.1016%2fj.clgc.2016.12.024&partnerID=40&md5=842515131636a2899d83d5866d553095

Fingerprint Dive into the research topics of 'First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study'. Together they form a unique fingerprint.

Cite this

Buti, S., Bersanelli, M., Maines, F., Facchini, G., Gelsomino, F., Zustovich, F., Santoni, M., Verri, E., De Giorgi, U., Masini, C., Morelli, F., Vitale, M. G., Sava, T., Prati, G., Librici, C., Fraccon, A. P., Fornarini, G., Maruzzo, M., Leonardi, F., & Caffo, O. (2017). First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. Clinical Genitourinary Cancer, 15(4), e609-e614. https://doi.org/10.1016/j.clgc.2016.12.024

First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. / Buti, S.; Bersanelli, M.; Maines, F.; Facchini, G.; Gelsomino, F.; Zustovich, F.; Santoni, M.; Verri, E.; De Giorgi, U.; Masini, C.; Morelli, F.; Vitale, M.G.; Sava, T.; Prati, G.; Librici, C.; Fraccon, A.P.; Fornarini, G.; Maruzzo, M.; Leonardi, F.; Caffo, O.

In: Clinical Genitourinary Cancer, Vol. 15, No. 4, 2017, p. e609-e614.

Research output: Contribution to journal › Article › peer-review

Buti, S, Bersanelli, M, Maines, F, Facchini, G , Gelsomino, F, Zustovich, F, Santoni, M, Verri, E , De Giorgi, U , Masini, C , Morelli, F, Vitale, MG, Sava, T, Prati, G, Librici, C, Fraccon, AP, Fornarini, G , Maruzzo, M, Leonardi, F & Caffo, O 2017, 'First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study', Clinical Genitourinary Cancer, vol. 15, no. 4, pp. e609-e614. https://doi.org/10.1016/j.clgc.2016.12.024

Buti, S. ; Bersanelli, M. ; Maines, F. ; Facchini, G. ; Gelsomino, F. ; Zustovich, F. ; Santoni, M. ; Verri, E. ; De Giorgi, U. ; Masini, C. ; Morelli, F. ; Vitale, M.G. ; Sava, T. ; Prati, G. ; Librici, C. ; Fraccon, A.P. ; Fornarini, G. ; Maruzzo, M. ; Leonardi, F. ; Caffo, O. / First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. In: Clinical Genitourinary Cancer. 2017 ; Vol. 15, No. 4. pp. e609-e614.

@article{65f18a9978734b5a98e250820a316077,

title = "First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study",

abstract = "Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. {\textcopyright} 2016 Elsevier Inc.",

keywords = "Chromophobe RCC, First-line treatment, nccRCC, Papillary RCC, Pazopanib",

author = "S. Buti and M. Bersanelli and F. Maines and G. Facchini and F. Gelsomino and F. Zustovich and M. Santoni and E. Verri and {De Giorgi}, U. and C. Masini and F. Morelli and M.G. Vitale and T. Sava and G. Prati and C. Librici and A.P. Fraccon and G. Fornarini and M. Maruzzo and F. Leonardi and O. Caffo",

note = "Export Date: 29 August 2017 Correspondence Address: Bersanelli, M.; University Hospital of Parma, Medical Oncology, Via Gramsci 14, Italy; email: bersamel@libero.it",

year = "2017",

doi = "10.1016/j.clgc.2016.12.024",

language = "English",

volume = "15",

pages = "e609--e614",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

AU - Buti, S.

AU - Bersanelli, M.

AU - Maines, F.

AU - Facchini, G.

AU - Gelsomino, F.

AU - Zustovich, F.

AU - Santoni, M.

AU - Verri, E.

AU - De Giorgi, U.

AU - Masini, C.

AU - Morelli, F.

AU - Vitale, M.G.

AU - Sava, T.

AU - Prati, G.

AU - Librici, C.

AU - Fraccon, A.P.

AU - Fornarini, G.

AU - Maruzzo, M.

AU - Leonardi, F.

AU - Caffo, O.

N1 - Export Date: 29 August 2017 Correspondence Address: Bersanelli, M.; University Hospital of Parma, Medical Oncology, Via Gramsci 14, Italy; email: bersamel@libero.it

PY - 2017

Y1 - 2017

N2 - Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. © 2016 Elsevier Inc.

AB - Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. © 2016 Elsevier Inc.

KW - Chromophobe RCC

KW - First-line treatment

KW - nccRCC

KW - Papillary RCC

KW - Pazopanib

U2 - 10.1016/j.clgc.2016.12.024

DO - 10.1016/j.clgc.2016.12.024

M3 - Article

VL - 15

SP - e609-e614

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 4

ER -